Acino Signs Exclusive License Agreement With Bioprojet for Treatment of Narcolepsy and Obstructive Sleeping Apnoea (OSA)

ZURICH, Switzerland, 14 June 2022 - Acino, a Swiss pharmaceutical company headquartered in Zurich, announced today that it has signed an exclusive licensing agreement with Bioprojet, a French research-based pharmaceutical company, to register, market, commercialise, and distribute pitolisant in the Kingdom of Saudi Arabia (KSA), with potential expansion to other countries in the Middle East.
Acino International AG Thurgauerstrasse 36/38 CH-8050 Zurich

+41 44 555 22 00